How should an acute migraine refractory to ketorolac, metoclopramide, dexamethasone, and diphenhydramine be managed?

Management of Acute Migraine Refractory to Standard Emergency Department Therapy

For acute migraine not responding to ketorolac, metoclopramide, dexamethasone, and diphenhydramine, administer a triptan (preferably subcutaneous sumatriptan) or dihydroergotamine (DHE) as the next-line migraine-specific therapy. 1, 2

Immediate Next Steps: Migraine-Specific Agents

Since the patient has failed NSAIDs (ketorolac), antiemetics (metoclopramide), and adjunctive therapy (dexamethasone, diphenhydramine), the evidence clearly directs you toward migraine-specific medications 1, 2, 1.

First Choice: Subcutaneous Sumatriptan

• Dosing: 6 mg subcutaneously, may repeat in 1 hour if needed (maximum 12 mg per 24 hours) 1
• Rationale: Reaches peak blood concentration in approximately 15 minutes—faster than any other migraine-specific medication—with 70-82% efficacy 1
• Contraindications: Screen for ischemic vascular disease, vasospastic coronary disease, uncontrolled hypertension, or significant cardiovascular disease 1

Alternative: Dihydroergotamine (DHE)

• Dosing: 0.5-1.0 mg IV or IM, can repeat every hour up to 3 mg IM or 2 mg IV per day 1
• Intranasal option: One 0.5-mg spray in each nostril, repeat in 15 minutes (maximum 2 mg/day) 1
• Contraindications: Cannot use if triptans already given, pregnancy, beta blockers, SSRIs, coronary artery disease 1

The 2025 American Headache Society guideline specifically recommends sumatriptan SC as "highly likely to be effective" for ED migraine treatment 3. The 2024 VA/DoD guideline also supports triptans and newer CGRP inhibitors (gepants) for acute migraine 4.

If Migraine-Specific Agents Fail or Are Contraindicated

Prochlorperazine (Compazine)

• Dosing: 10 mg IV 1
• Evidence: The 2025 guideline rates prochlorperazine as "highly likely to be effective" (Level A - must offer) 3
• Advantage: Can effectively relieve headache pain, not just nausea 1
• Caution: 6% risk of severe akathisia ("very restless" feeling) 5; consider prophylactic diphenhydramine if not already given

Chlorpromazine

• Evidence: Likely effective based on Class I studies 2, 3
• Dosing: Typically 12.5-25 mg IV slowly
• Advantage: Superior or equivalent to most other treatments 6
• Caution: Higher risk of akathisia and sedation; requires blood pressure monitoring

Critical Pitfalls to Avoid

Do NOT Use Opioids as Rescue Therapy

Hydromorphone and meperidine must not be offered (Level A recommendation) 3. While older guidelines suggested opioids like meperidine or butorphanol "are sometimes required" 1, the most recent 2025 evidence shows:

• Hydromorphone IV is "likely ineffective" 3
• Opioids lead to dependency, rebound headaches, and eventual loss of efficacy 1
• Meperidine was inferior to chlorpromazine and only equivalent to other neuroleptics 6

Valproate Is Inferior

A 2014 Class I study demonstrated IV valproate (1000 mg) improved pain by only 2.8 points on a 0-10 scale compared to 4.7 for metoclopramide and 3.9 for ketorolac, with 69% requiring rescue medication 5. Do not use valproate as rescue therapy.

Additional Dexamethasone Won't Help Acutely

Since dexamethasone has already been given, adding more won't provide immediate relief. A 2023 trial showed no difference between 4 mg and 16 mg dexamethasone when combined with metoclopramide 7. Dexamethasone's role is preventing recurrence after discharge, not acute pain relief 1.

Alternative Approaches

Nerve Blocks (If Available)

• Greater occipital nerve block (GONB): "Highly likely to be effective" (Level A - must offer) 3
• Supraorbital nerve block (SONB): "Likely effective" (Level B - should offer) 3
• These provide rapid relief without systemic medication concerns

Non-Oral Triptans (If Oral Route Compromised)

• Intranasal sumatriptan: 5-10 mg (one to two sprays), may repeat after 2 hours (maximum 40 mg/day) 1
• Intranasal zolmitriptan: Alternative option 2, 1

Discharge Planning

Once acute pain is controlled:

• Prescribe oral triptan for home use if attacks recur 1, 2
• Consider preventive therapy if patient has ≥2 attacks per month causing disability lasting ≥3 days 2
• Avoid frequent ED visits: Develop outpatient oral rescue protocol with antiemetic suppository followed by oral triptan 8

Key Algorithmic Decision Points

1. Has the patient received a triptan or DHE yet? → No → Give subcutaneous sumatriptan 6 mg
2. Cardiovascular contraindications to triptans/DHE? → Yes → Give prochlorperazine 10 mg IV
3. Failed triptan/DHE? → Give prochlorperazine or chlorpromazine
4. Still refractory? → Consider nerve block if available, or admit for status migrainosus management
5. Never escalate to opioids → They are ineffective and harmful 3, 6

The evidence strongly supports migraine-specific agents (triptans, DHE) or dopamine antagonists (prochlorperazine, chlorpromazine) as the appropriate next steps, with opioids explicitly contraindicated despite their historical use 1, 2, 3, 9.